IDEAYA BIOSCIENCES INC (IDYA)

Company Profile

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The company is headquartered in South San Francisco, California and currently employs 122 full-time employees. The company went IPO on 2019-05-23. The firm is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates are darovasertib (IDE196), IDE397 and IDE161. IDE196, a small molecule protein kinase C (PKC), inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397, is its small molecule methionine adenosyltransferase 2a (MAT2A), inhibitor. IDE161, is its small molecule poly (ADP-ribose) glycohydrolase (PARG), inhibitor. IDE196 is its clinical-stage PKC inhibitor that the Company is evaluating as a synthetic lethal combination therapy. IDE397, a MAT2A inhibitor for patients with solid tumors having MTAP deletions. IDE161 is its clinical-stage, potent and selective small molecule inhibitor of PARG for patients having tumors with defined biomarkers based on genetic mutations and/or molecular signatures.

Company Info

IDEAYA BIOSCIENCES INC

7000 Shoreline Ct Ste 350

South San Francisco CALIFORNIA 94080

P: 16504436209

CEO: Yujiro Hata

Employees: 122

Website: https://www.ideayabio.com/